Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

QUEST DIAGNOSTICS INC (DGX)

CIK 0001022079 4 material events

Insider activity (SEC Form 4)

Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.

Open-market · last 30 days: 0 buyers bought $0 4 sellers sold $11.9M
Open-market · last 90 days: 0 buyers bought $0 6 sellers sold $19.8M
InsiderRoleDateTransactionSharesValue
Deppe Michael J SVP, Corp. Controller & CAO 2026-11-13 Option exercise 10b5-1 6261 $600K
Deppe Michael J SVP, Corp. Controller & CAO 2026-11-13 Open-market sell 10b5-1 6261 $1.6M
Deppe Michael J SVP, Corp. Controller & CAO 2026-11-13 Option exercise 10b5-1 5515 $571K
Deppe Michael J SVP, Corp. Controller & CAO 2026-11-13 Open-market sell 10b5-1 5515 $1.4M
Plewman Patrick SVP for Diagnostic Services 2026-11-09 Option exercise 10b5-1 4274 $546K
Plewman Patrick SVP for Diagnostic Services 2026-11-09 Open-market sell 10b5-1 4274 $1.1M
Plewman Patrick SVP for Diagnostic Services 2026-11-09 Option exercise 10b5-1 6793 $868K
Plewman Patrick SVP for Diagnostic Services 2026-11-09 Open-market sell 10b5-1 6793 $1.7M
Plewman Patrick SVP for Diagnostic Services 2026-11-09 Open-market sell 10b5-1 650 $167K
DELANEY MARK E SVP & Chief Commercial Officer 2026-11-03 Grant/award 2615 $0
Doherty Catherine T. Executive Vice President 2026-11-03 Grant/award 10b5-1 4827 $0
Doherty Catherine T. Executive Vice President 2026-11-03 Option exercise 10b5-1 22105 $2.7M
Doherty Catherine T. Executive Vice President 2026-11-03 Open-market sell 10b5-1 3818 $937K
Doherty Catherine T. Executive Vice President 2026-11-03 Open-market sell 10b5-1 5990 $1.5M
Doherty Catherine T. Executive Vice President 2026-11-03 Open-market sell 10b5-1 1151 $284K
Doherty Catherine T. Executive Vice President 2026-11-03 Open-market sell 10b5-1 2358 $586K
Doherty Catherine T. Executive Vice President 2026-11-03 Open-market sell 10b5-1 3004 $749K
Doherty Catherine T. Executive Vice President 2026-11-03 Open-market sell 10b5-1 2877 $721K
Doherty Catherine T. Executive Vice President 2026-11-03 Open-market sell 10b5-1 2907 $730K
Ramachandran Subu SVP, Regional Businesses 2026-11-03 Grant/award 352 $0
Most recent 20 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.

Risk Radar (year-over-year Risk Factors)

← All Risk Radar

Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →

The FDA LDT regulatory overhang materially lifted following the March 2025 court vacatur, but three new risk vectors emerged that collectively offset the relief: tariff and trade-policy exposure now threatens supply chain costs and product availability, third-party consumer health partnerships introduce fresh data-handling and contractual liability, and M&A activity now carries added antitrust clearance and direct-to-consumer regulatory complexity. On balance, the risk profile shifted in multiple directions simultaneously, with the new exposures concentrated in operationally sensitive areas.

2 company-specific · 1 eased/removed · 1 common-mode

Company-specific changes

Revised

New disclosure of third-party health data handling risk via consumer health service partnerships, creating contractual and regulatory exposure not previously disclosed.

Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies. In our business, we collect, generate, process or maintain…

Revised

Added regulatory clearance/antitrust risk to M&A process; new disclosure of direct-to-consumer health services exposure with CLIA, corporate practice of medicine, and reimbursement risks.

Business development activities are inherently risky and integrating our operations with businesses we acquire may be difficult. We plan selectively to enhance our business from time to time through…

Eased / removed

Revised

FDA LDT rule vacated by court in March 2025; FDA lost regulatory authority. Prior year described imminent four-year compliance burden; risk materially eased.

Our business and operations could be adversely impacted by the FDA's approach to regulation. The FDA has regulatory responsibility over, among other areas, instruments, software, test systems…

Also disclosed — common-mode (Tariffs trade policy)
Tariffs trade policy Revised

Added substantive disclosure of tariffs, sanctions, and trade policy risks with explicit impact on supply chain costs and product availability.

We are subject to numerous political (including geopolitical), legal, operational and other risks as a result of our international operations which could impact our business in many ways. Our…

Material year-over-year changes to this company's Risk Factors (Item 1A), found by comparing each annual report to the prior year, judged for materiality, and classified as company-specific or common-mode against the cross-company catalog. Common-mode changes are the macro themes many companies disclose in common; they are collapsed above. A filing marked unchanged had no material change from the prior year; its summary describes the company's standing risks, which remain in force. Fiscal periods are the reporting period ends. Not investment advice.

Cybersecurity Incident

8-K filed 2026-10-22 confidence 95% Item 8.01

Quest Diagnostics disclosed unauthorized access to its Quanum LSM system on October 21, 2026, involving access to certain patient records. The company promptly initiated incident response procedures, notified federal law enforcement, and engaged external cybersecurity experts. This is a material cybersecurity incident involving patient data breach at a major diagnostic services provider, meeting the definition of cybersecurity_incident under Item 1.05 (required disclosure since 2023).

View raw filing on EDGAR →

Earnings release

8-K filed 2026-10-22 confidence 98% Item 2.02

Quest Diagnostics issued a press release on October 22, 2026 announcing third quarter 2026 financial results, including Q3 revenues of $3.10 billion (up 10.0% YoY), diluted EPS of $2.78 (up 28.7% YoY), and adjusted diluted EPS of $3.00 (up 15.4% YoY). The company also raised full-year 2026 revenue and EPS guidance. This is a standard quarterly earnings release disclosure under Item 2.02, with the press release attached as Exhibit 99.1.

View raw filing on EDGAR →

Earnings release

8-K filed 2026-07-23 confidence 99% Item 2.02

Quest Diagnostics issued a press release on July 23, 2026 announcing second quarter 2026 financial results, including net revenues of $3.04 billion (up 10.2% YoY), diluted EPS of $2.84 (up 15.0% YoY), and adjusted diluted EPS of $3.12 (up 19.1% YoY). The company also raised full-year 2026 guidance for both revenues and EPS. This is a standard quarterly earnings release with detailed financial statements and forward guidance, clearly falling under Item 2.02 disclosure requirements.

View raw filing on EDGAR →

Shareholder vote

8-K filed 2026-05-21 confidence 98% Item 5.07

This is a classic Item 5.07 disclosure presenting the voting results from Quest Diagnostics' 2026 Annual Meeting of Stockholders held on May 20, 2026. The filing reports results for four distinct matters: election of 11 directors, advisory approval of executive compensation, ratification of PricewaterhouseCoopers as independent auditor, and a shareholder proposal on independent board chairman. All directors were elected with substantial majorities, compensation was approved, and the auditor was ratified, while the board chairman proposal failed. These results are material to investors assessing governance and board composition.

View raw filing on EDGAR →